MX2016012718A - Determinación de polimorfismos de un solo nucleótido útil para predecir la respuesta para rasagilina. - Google Patents

Determinación de polimorfismos de un solo nucleótido útil para predecir la respuesta para rasagilina.

Info

Publication number
MX2016012718A
MX2016012718A MX2016012718A MX2016012718A MX2016012718A MX 2016012718 A MX2016012718 A MX 2016012718A MX 2016012718 A MX2016012718 A MX 2016012718A MX 2016012718 A MX2016012718 A MX 2016012718A MX 2016012718 A MX2016012718 A MX 2016012718A
Authority
MX
Mexico
Prior art keywords
rasagiline
human subject
single nucleotide
determination
pharmaceutically acceptable
Prior art date
Application number
MX2016012718A
Other languages
English (en)
Inventor
Eyal Eli
MASELLIS Mario
Knight Joanne
Shannon Collinson Maureen
Edward Lang Anthony
Lowery KENNEDY James
Levy Joseph
Ofra Barnett
Tchelet Amir
Grossman Iris
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of MX2016012718A publication Critical patent/MX2016012718A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

Esta solicitud proporciona un método para tratar un sujeto humano que padece mal de Parkinson (PD) con una composición farmacéutica que comprende rasagilina o una sal farmacéuticamente aceptable de rasagilina, y un portador farmacéuticamente aceptable, que comprende los pasos de: (i) obtener una muestra biológica que comprende un genoma del sujeto humano que padece mal de Parkinson; (ii) someter a ensayo el ADN o ARN de la muestra biológica del sujeto humano usando una sonda o un cebador para determinar el genotipo diploide del sujeto humano en un polimorfismo de un solo nucleótido (SNP) rs1076560 o rs2283265; (iii) identificar al sujeto humano como un sujeto que responde predicho a la rasagilina si el genotipo diploide es CC en rs1076560, CC en rs2263265, o CC en tanto rs1076560 como rs2283265; y (iv) administrar la composición farmacéutica que comprende rasagilina y un portador farmacéuticamente aceptable al sujeto humano si el sujeto humano se identifica como un sujeto que responde predicho a la rasagilina.
MX2016012718A 2014-04-01 2015-03-31 Determinación de polimorfismos de un solo nucleótido útil para predecir la respuesta para rasagilina. MX2016012718A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461973603P 2014-04-01 2014-04-01
PCT/US2015/023618 WO2015153629A1 (en) 2014-04-01 2015-03-31 Determination of single nucleotide polymorphisms useful to predict response for rasagiline

Publications (1)

Publication Number Publication Date
MX2016012718A true MX2016012718A (es) 2016-12-16

Family

ID=54189487

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016012718A MX2016012718A (es) 2014-04-01 2015-03-31 Determinación de polimorfismos de un solo nucleótido útil para predecir la respuesta para rasagilina.

Country Status (9)

Country Link
US (1) US20150275302A1 (es)
EP (1) EP3126527A4 (es)
JP (1) JP2017517481A (es)
AR (1) AR099950A1 (es)
CA (1) CA2943841A1 (es)
IL (1) IL247824A0 (es)
MX (1) MX2016012718A (es)
TW (1) TW201621051A (es)
WO (1) WO2015153629A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017087735A1 (en) * 2015-11-18 2017-05-26 Millennium Pharmaceuticals, Inc. Method for treating crohn's disease
CN107941953A (zh) * 2017-11-30 2018-04-20 天津生机集团股份有限公司 一种兽药中金刚烷胺药物残留的检测方法
CN109825572A (zh) * 2019-03-13 2019-05-31 陈向东 一种检测与异丙酚的敏感性相关基因多态性的试剂盒及其检测方法
CN118406755B (zh) * 2024-07-02 2024-09-10 解码（上海）生物医药科技有限公司 一种指导帕金森病用药的基因多态性检测引物组及试剂盒

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2631675A1 (en) * 2005-11-30 2007-06-21 The University Of North Carolina At Chapel Hill Identification of genetic polymorphic variants associated with somatosensory disorders and methods of using the same
WO2008017002A2 (en) * 2006-08-01 2008-02-07 The Ohio State University Research Foundation Polymorphisms in genes affecting cns disorders and uses thereof
MX2010013766A (es) * 2008-06-13 2011-03-15 Teva Pharmaceutical Ind Ltd Star Rasagilina para modificacion de enfermedad de parkinson.
EP2406396A2 (en) * 2009-03-12 2012-01-18 Brainco Biopharma, S.L. A genotyping tool for improving the prognostic and clinical management of ms patients

Also Published As

Publication number Publication date
EP3126527A1 (en) 2017-02-08
AR099950A1 (es) 2016-08-31
JP2017517481A (ja) 2017-06-29
TW201621051A (zh) 2016-06-16
WO2015153629A1 (en) 2015-10-08
US20150275302A1 (en) 2015-10-01
IL247824A0 (en) 2016-11-30
CA2943841A1 (en) 2015-10-08
EP3126527A4 (en) 2017-10-04

Similar Documents

Publication Publication Date Title
WO2015123430A3 (en) Single molecule electronic multiplex snp assay and pcr analysis
WO2014116729A3 (en) Haplotying of hla loci with ultra-deep shotgun sequencing
NZ600235A (en) Methods and compositions for the assessment of drug response
WO2007130519A3 (en) Viral nucleic acid microarray and method of use
WO2016130572A3 (en) Methods of determining levels of exposure to radiation and uses thereof
MX2016012718A (es) Determinación de polimorfismos de un solo nucleótido útil para predecir la respuesta para rasagilina.
BR112012030813A2 (pt) "métodos e kits para detecção in situ de sequências de nucleotídeo"
WO2008132763A3 (en) Genetic variants useful for risk assessment of coronary artery disease and myocardial infarction
WO2007058968A3 (en) Gene expression profiles and methods of use
MX2010005060A (es) Identificacion y mapeo a base de microarreglos de adn de puntos de ruptura de translocacion equilibrados.
NZ591711A (en) A method for predicting athletic performance potential
MX2013008252A (es) Firma de pronostico para la recurrencia de cancer colorrectal.
BRPI0809143B8 (pt) método in vitro para identificar um indivíduo que apresente um risco alterado para desenvolver doença cardíaca coronária (chd) ou aneurisma/dissecção
NZ604125A (en) Prediction of hcv viral kinetics in interferon-free treatment
AR104348A1 (es) Polimorfismos de un solo nucleótido seleccionados que son predictivos de respuestas al acetato de glatirámero
WO2010034690A3 (en) Method for lowering the dependency towards sequence variation of a nucleic acid target in a diagnostic hybridization assay
GB0517466D0 (en) Diagnostic assay and therapeutic treatment
RU2012119187A (ru) Технология определения трисомии хромосом методом секвенирования
WO2016090001A9 (en) Deep intronic mutation found adult polyglucosan body disease and uses thereof
WO2010081764A3 (de) Genomweite analyse zur endothelialen dysfunktion
JP2020178568A5 (es)
UA95942U (uk) Спосіб прогнозування зрощення перелому
WO2020162663A9 (ko) 성조숙증 진단 또는 치료 예후 예측용 단일염기다형성 마커 및 이의 용도
MY175723A (en) Oligonucleotides and a method for detecting and/or quantifying human metapneumovirus (hmpv)
NZ588905A (en) Genetic testing method for determining susceptibility to abdominal aortic aneurysm by assay for selected polymorphisms associated with the disease